Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia

Waters, 2006, What the statin trials have taught us, Am J Cardiol, 98, 129, 10.1016/j.amjcard.2006.01.066 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E Martin, 2013, Modifiable factors associated with failure to attain low-density lipoprotein cholesterol goal at 6 months after acute myocardial infarction, Am Heart J, 165, 26, 10.1016/j.ahj.2012.10.005 Virani, 2011, Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease, Am Heart J, 162, 725, 10.1016/j.ahj.2011.07.013 Pinkosky, 2013, AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism, J Lipid Res, 54, 134, 10.1194/jlr.M030528 Srivastava RA, Hurley TR, Brant AF, et al. A novel small molecule, ETC-1002, lowers proatherogenic lipoproteins, reduces adiposity, and improves hepatic steatosis in a hyperlipidemic hamster model (abstr 25085). Presented at: American Heart Association Scientific Sessions 2011; November 12–16, 2011; Orlando, FL. Hanselman JC, Bradshaw CD, Brant AF, et al. ETC-1002 reduces circulating and hepatic triglyceride content and improves glycemic control in KKAy mice (abstr 554). Presented at: ATVB Scientific Sessions 2011; April 28–30, 2011; Chicago, IL. Cramer, 2004, Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome, J Lipid Res, 45, 1289, 10.1194/jlr.M400018-JLR200 Myers, 1989, The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements, Clin Lab Med, 9, 105, 10.1016/S0272-2712(18)30645-0 Rabinovitch, 2002, The College of American Pathologists laboratory accreditation program, Accred Qual Assur, 7, 473, 10.1007/s00769-002-0537-0 Warnick, 1978, A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol, J Lipid Res, 19, 65, 10.1016/S0022-2275(20)41577-9 Friedewald, 1972, Estimation of concentration of low density lipoprotein cholesterol in plasma, without using preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 1982 Jeyarajah, 2006, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Clin Lab Med, 26, 847, 10.1016/j.cll.2006.07.006 Roger, 2012, Heart and stroke statistics—2012 update: a report from the American Heart Association, Circulation, 125, e2 Heidenreich, 2011, Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, Circulation, 123, 933, 10.1161/CIR.0b013e31820a55f5 Egan, 2011, Weighting the benefits of high-dose simvastatin against the risk of myopathy, N Engl J Med, 365, 285, 10.1056/NEJMp1106689 Cohen, 2012, Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users, J Clin Lipidol, 6, 208, 10.1016/j.jacl.2012.03.003 Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6 Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy, JAMA, 305, 2556, 10.1001/jama.2011.860 US Food and Drug Administration. FDA Drug Safety Communication: Important safety label changes to cholesterol lowering statin drugs [press release]. Available at: http://www.fda.gov/Drugs/Drug Safety/ucm293101.htm. Accessed February 1, 2013. Knopp, 2003, Evaluation of the efficacy, safety and tolerability of ezetimibe in primary hypercholesterolemia: a pooled analysis from two controlled phase III clinical studies, Int J Clin Pract, 57, 363, 10.1111/j.1742-1241.2003.tb10508.x Insull, 2001, Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial, Mayo Clin Proc, 76, 971, 10.4065/76.10.971 Goldberg, 1998, Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study, Am J Cardiol, 82, 35U, 10.1016/S0002-9149(98)00952-7 Knopp, 1987, Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia, Am J Med, 83, 50, 10.1016/0002-9343(87)90871-0 Hellerstein, 1999, De novo lipogenesis in humans: metabolic and regulatory aspects, Eur J Clin Nutr, 53, S53, 10.1038/sj.ejcn.1600744 Ascasso, 2003, Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism, Diabetes Care, 26, 3320, 10.2337/diacare.26.12.3320 Ridker, 2008, Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein, N Engl J Med, 359, 2195, 10.1056/NEJMoa0807646 Dierkes, 2001, Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels, Vascular Health and Risk Management, 3, 99